Summary In contrast to reports of extensive hypoxia in human gliomas in situ measured by P02 histography, non-invasive methods of assessing glioma oxygenation, including nitroimidazole binding, have yielded surprisingly contradictory results. In order to investigate the relationship of necrosis, hypoxia, nitroreductase activity and cellular respiration in human gliomas, subcutaneous models using the human glioma cell lines M059K, M006 and M01 Ob were developed in the murine SCID host. Intracranial growth of the M006 line was achieved in nude rats. The nitroreductive capacity of glioma cell lines was assessed and found to be similar to transplanted tumours previously reported in the literature. This suggests that if substantial numbers of viable hypoxic cells were present in situ in gliomas, then nitroimidazole-binding techniques should be capable of identifying them. Inter-tumour variability in the amount of necrosis was seen. M006 xenografts growing in subcutaneous and intracranial sites revealed extensive necrotic regions histologically, some of which were surrounded by cells labelled heavily for [3H]misonidazole, while other areas were lightly labelled. Similar binding patterns were seen for subcutaneous M059K tumours, while subcutaneous M01 Ob tumours display necroses of which almost all were surrounded by heavily labelled cells. The oxygen consumption rates of tumour cell lines grown in vivo, in which venous P02 concentrations are of the order of 2-5%, were two to sevenfold less than those of the same lines grown as monolayers in vitro under oxygen concentrations of 18%. We postulate that glioma cell lines behave as 'oxygen conformers', in that their rate of oxygen consumption appears to vary with the availability of oxygen. Together with the misonidazole-binding data, the results in this glioma tumour model are consistent with coordinate inhibition or down-regulation of respiration under moderate hypoxia.
Malignant gliomas are highly cellular tumours which normally contain necrosis (Nelson J et al, 1983; Wilden et al, 1987) and which are commonly assumed to contain substantial numbers of hypoxic cells. Almost all macroscopic transplanted tumours in rodents contain viable hypoxic cells, which are a major cause of radioresistance (Moulder and Rockwell, 1984; Rockwell and Moulder, 1990) . However, the incidence and natural history of hypoxia in human brain tumours before and during radiotherapy is poorly understood. The benefit of the use of hypoxic cell radiosensitizers with radiotherapy for gliomas was has been reported for metronidazole (Urtasun et al, 1976) but not for misonidazole (Bleehen et al, 1981; Nelson D et al, 1983; Green et al, 1984) .
Attempts to identify tumour hypoxia in human gliomas using nitroimidazole adduct techniques have yielded unexpected results. No evidence for hypoxia was obtained in a series of human glioblastomas imaged with [1231] iodoazomycin arabinoside (['231 ]IAZA) despite the fact that avidity for this compound was noted in 75% of the brain metastases studied and in 40% of extracranial tumours (Groshar et al, 1993; Urtasun et al, 1996) .
['tF]Fluoromisonidazole imaging data in glioma are limited, however increased fluoromisonidazole uptake relative to plasma has arguably been demonstrated in only one of three patients reported (Valk et al, 1992) .
Positron emission tomographic (PET) studies on the metabolic use of oxygen in breast and brain tumours in situ have been reported (Ito et al, 1982; Lammertsma et al, 1985; Brooks, 1990) . In these studies, the tumour oxygen extraction ratio (OXR) was used as an indirect indicator of hypoxia, assuming that hypoxic tumour tissue would extract a greater fraction of oxygen from capillary blood than aerobic tumour or normal tissue. These studies demonstrated elevated tumour OXR relative to normal tissue in individual breast tumours; however, elevated OXRs were not seen in malignant gliomas, and indeed the tumour OXR was lower than in normal brain, consistent with diminished oxygen consumption in the tumours. These imaging techniques rely on the averaging of signals from relatively large volumes of tissue, hence the presence of smaller volumes of hypoxic cells within microregions that maximally extract available oxygen cannot be excluded. However, if both nitroimidazole binding and '50-PET data sets are correct, they predict that the majority of gliomas do not contain large regions of viable, chronically hypoxic cells.
In contrast, pO2 histography in human gliomas in situ during anaesthesia has suggested extensive hypoxia in the lesions themselves and in peritumoral oedema (Cruickshank and Rampling, 1994a, b; Rampling et al, 1994) . These data appear to support the clinical trials currently underway testing the therapeutic role of hypoxic cytotoxins in malignant gliomas. However, electrodes are unable to distinguish between viable tumour tissue and acellular necrosis, and the effect of anaesthesia upon the oxygen electrode measurements in the brain remains to be defined.
These conflicting lines of evidence lead us to develop tumour models which could be used to examine the anomalous nitroimidazole-binding characteristics and oxygenation status of gliomas. Our objectives were to test two hypotheses for the failure of [123111AZA to detect hypoxic regions in human gliomas, namely
(1) inadequate drug delivery or intracellular uptake and (2) altered kinetics of nitroimidazole bioreduction by glioma reductases. It is recognized that, particularly in deeper portions of the tumour adjacent to necrosis, the vasculature of large intact gliomas is disrupted (Krauseneck and Muller, 1995) . For this reason, inadequate IAZA transport across the blood-brain barrier to the putative hypoxic glioma cells was considered the least probable explanation. In this report, we show that human glioma cell lines growing as subcutaneous or intracranial xenografts in immune-deficient rodents variably display evidence of necrosis; some necroses are surrounded by cells which are heavily labelled by [1251I]IAZA or the prototypic hypoxia marker [3H]misonidazole, while others unexpectedly are not. In experiments testing the kinetics of nitroimidazole bioreduction in vitro, results consistent with the kinetics of this process in murine and other human tumours were obtained. These results suggest an additional hypothesis i.e. under conditions of constrained oxygen supply, oxygen consumption is down-regulated and development of necrosis (at least in some microregions) may occur through the depletion of substrates other than oxygen, perhaps because of an inability to meet the demands of aerobic glycolysis (Kormblith et al, 1984; Wise et al, 1984) . This report describes the in vitro and in vivo tumour systems used to test these hypotheses.
MATERIALS AND METHODS

Cell lines
The glioma cell lines used in these studies were derived from portions of diagnostic biopsies obtained from patients with glioblastoma and were supplied by Dr RS Day III. The procedures used to dissociate the tumour specimens and to establish the cell lines have been previously published (Allalunis-Tumer et al, 1991) . The M0059K cell line was derived from the biopsy of a grade IV astrocytoma with focal necrosis, vascular proliferation and occasional gemistocytes. The M006 line was derived from a grade IV astrocytoma with a relatively low mitotic index, prominent vascular endothelial proliferation and extensive necrosis. The MO lOb line was derived from an anaplastic astrocytoma showing moderate pleomorphism, frequent mitoses, vascular endothelial proliferation but no giant cells or necrosis. Monolayer cultures were prepared using M006, M059K and MO lOb cells thawed from frozen stock. The cultures were maintained in Dulbecco's modified Eagle Medium (DMEM)-F12 with 10% fetal calf serum (Gibco, Grand Island, NY, USA).
Xenografts
All animal experiments were performed according to guidelines for the use of animals in research established by the Canadian Council for Animal Care. SCID mice and nude rats used for xenograft transplantation were housed in filter-topped cages in a clean barrier facility and fed autoclaved rodent chow ad libitum. C.B. 17 SCID mice obtained from Jackson (Bar Harbor, ME, USA) and bred at the Health Sciences Laboratory Animal Services, University of Alberta, Canada, were used for the M0059J, M006 and MOOlOb lines. C.B.-17/IcrCrl-scid mice from Charles River (St Constant, Quebec) were used for sublines (MOO59KX and M006X). Tumours were initiated in mice 6 to 10 weeks of age by subcutaneous injection of 106 to 107 cells in both flanks. Tumour growth was monitored by weekly or biweekly calliper measurements taken in three orthogonal directions. Tac:N:NIH-rnufDF nude rats were obtained from Taconic (Germantown, NY, USA) and received 5 Gy whole-body irradiation (137Cs, Shepherd Mark I, Shepherd and Associates, San Fernando, CA, USA) at 5 weeks of age. The next day, 2.5 x 104 M006 tumour cells in 0.05 ml of saline were injected at a single intracerebral site over a 5-min period. The site was 3 mm below the surface of the brain through a burr hole located 2 mm posterior and 3 mm lateral to the bregma.
[3H]Misonidazole, with a specific activity of 15.6 mCi mg-' (580 MBq mg-') was synthesized following a published procedure (Born and Smith, 1983) . It was diluted with cold misonidazole to a final specific activity of between 820 and 3700 tCi mg-' for labelling tumour-bearing mice and rats in vivo and tumour frag- ['251]sodium iodide (Amersham Canada) as a dry residue in a small v-vial was treated with 0.6 mg of IAZA and 3.3 mg of pivalic acid in methanol. The solvent was removed at 40°C under a stream of nitrogen gas. The residue was heated at 780C for 75 min to effect the exchange labelling. The crude product was purified by preparative liquid chromatography on a reverse-phase column (Whatman). The final product had a specific activity of 94 ,uCi mg-' (3.5 MBq mg-') and was injected into tumour-bearing mice at an initial whole-body concentration of 84 gM.
Mice were injected with nitroimidazoles when tumour volumes equalled 100-300 mm3. The required quantity of drug was dissolved in saline, and 0.2 ml was injected intraperitoneally three times at hourly intervals. The mice were euthanized 1 h after the last injection, and the tumours were excised and cut into two or four pieces, depending on the initial size of the tumour. Half of the pieces were fixed in 10% buffered formalin for 24 h at 4°C, then for 2-6 days at room temperature, and the remaining pieces were fixed in 100% ethanol for 24 h at 4°C. The rats bearing intracranial tumours were labelled with [3H]misonidazole as soon as any indications of tumour development were observed (unusual eye or eyelid motion, abnormal posture, lethargy, balance problems, partial paralysis of any limb). Two intraperitoneal injections were given at 1.5 h intervals (hourly injections were unnecessary because of the longer half-life of misonidazole in the blood of rats) . The rats were euthanized 1.5 h after the last injection, and the tumours were fixed in formalin as above.
The tumours were embedded in wax, sectioned at 5 ,um and placed on slides which, in the case of the ethanol-fixed portions, had been coated with poly-L-lysine. The sections were dewaxed with xylene, rehydrated and dipped in NTB-2 Nuclear Track Emulsion (Kodak, Rochester, NY, USA) for autoradiography. The emulsion was exposed for 1 to 6 weeks, developed and the tissues were stained with haematoxylin and eosin.
Nitroreductive activity of glioma tissue in vitro was assessed as a function of oxygen concentration using an established technique (Franko et al, 1987) . Unlabelled M006 and MOlOb tumours were excised and cut into roughly cubic fragments (largest dimension 2 mm) which were incubated with [3H]misonidazole in minimal essential medium at several oxygen concentrations for 3 h at 37°C. The only modification to the previously published methods (Franko et al, 1987) was to incubate each fragment separately in chambers created within the 60-mm glass Petri dishes by installing glass partitions. This avoided clumping of the fragments on the shaker table. Tissue fragments were fixed in formalin, embedded in wax and sectioned, and autoradiography was used as above to quantify the distribution of misonidazole adducts at the fragment surface and on sections which passed near the centre of each fragment. A grid of 10-gm squares was aligned perpendicular to the tissue surface, and the grains in successive squares were recorded along ten randomly chosen tracks for each oxygen level. Additional counts over randomly chosen cells at the surface of fragments were taken using the 10-gm squares of the grid.
Oxygen consumption
In order to measure oxygen consumption of monolayer cultures, cells in exponential growth or plateau phase were trypsinized and resuspended in complete medium. Oxygen consumption was determined using a Clark-type electrode (Koch, 1984) , which measured the oxygen concentration continuously in the cell suspension in a specially designed spinner chamber held in a 370C water bath. To measure the oxygen consumption rate of xenograft explants, subcutaneous tumours were minced into 1-2 mm cubes and enzymatically disaggregated to single cells as previously described (Allalunis-Turner and Siemann, 1986), washed and resuspended in complete medium. The oxygen consumption rate was calculated from the linear portion of the oxygen consumption curve and was determined within the first hour after electrode stabilization.
RESULTS
Growth characteristics and histology
Of 12 early passage human glioma cell lines selected for xenograft transplantation, only three (M006, M059K and MOlOb) successfully developed tumours larger than 50 mm3. The latent periods (taken as the time to achieve a volume of 20 mm3) ranged from 6 to 14 weeks, and the doubling times thereafter were 1-2 weeks. Sublines were derived by disaggregating these xenografted tumours using the same techniques as had been used to derive the original lines from biopsy material. Sublines are designated with a terminal X, e.g. M006X. Tumours from the sublines generally exhibited a reduced latent period of 1-2 weeks, while the subsequent growth rates were similar to those of the original xenografts. The histological features of the diagnostic biopsy obtained from the patients from whom these tumour cell lines were derived were compared with the subsequently derived xenograft histologies. It is recognized that the tumour stroma and vasculature are derived from the SCID mouse host and that changes in histological architecture may appear on this basis. Overall, the lines investigated appear to have reproduced some, but not all, of the features of the original tumours. Typically, the M059K tumours showed closely aggregated cells with prominent nuclei and mitotic activity with rare multinuclear giant cells present. Extensive necrosis was seen in 25% of tumours derived from the M059K line. In the M059KX tumours, representing the second passage in vivo, the neoplastic cells were similar in appearance, and there were wider fields of aUnpublished data (Franko, 1989 (Franko, ,1994 . bFranko et al (1987) . cFranko et al (1992) .
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dThe 'X' cell line designates a cell line which was established in vitro from disaggregated tumour xenografts. All 'X'-line oxygen consumption measurements were performed on exponential phase cells.
labelling in the centre. Tumour cubes were also incubated at several lower levels of oxygen. The dependence of grain density upon distance from the surface of the tumour fragment is shown in Figure 2 . Elevated marker density is seen starting 150 gm from the surface of the MO lOb tumour fragments (Figure 2A ) at the highest oxygen concentration, reaching a maximum after 250 gm. The binding pattern is somewhat different in the M006X fragments ( Figure 2B ) where elevated density is seen starting at 70 jim at the highest oxygen concentration, reaching a maximum at 250 ,um. For progressively lower oxygen concentrations, the grain density begins to rise correspondingly closer to the surface of the fragment. In severe hypoxia, high grain density is seen extending to the surface of the fragment. The relationship between misonidazole binding and oxygen level is shown in Figure 3 , for which additional scoring was performed at the surface of M006X and MOlOb tumour fragments. Assessment of the M059K tumour was not possible because lymphocytes had migrated to the surface of fragments of this tumour. These results suggest that the bioreductive enzymes required to form nitroimidazole adducts were present in glioma tissues and that nitroimidazole binding was oxygen sensitive in vitro. As misonidazole binding occurs as a linear function of time, binding rates can be calculated (Chapman et al, 1983 ). The binding rates (expressed as grain densities) of misonidazole to fragments of tumours of a wide variety of histologies under severe hypoxia have been compared in Table 1 . Assuming that the binding rate varies with the square root of drug concentration under severe hypoxia (Koch et al, 1984) and correcting for differences in exposure time and specific activity, it is possible to calculate an adjusted grain density. The mean adjusted grain density for the three glioma xenografts is 62.0 ± 7.21 grains per 100 jim2, close to the mean density of 75.2 ± 19.9 grains per 100 jm2 observed in five tumours studied previously.
Oxygen consumption
In order to determine if the ability to reduce oxygen consumption rate in response to decreased availability of molecular oxygen may be an adaptive response in gliomas, the rate of oxygen utilization of exponential and plateau-phase monolayers and cells freshly dissociated from tumours was compared. The results shown in Table 2 indicate that glioma cell lines vary in their rate of oxygen consumption and that glioma cells isolated from subcutaneous xenografts from all three lines had a significantly reduced rate of oxygen consumption, compared with that of the same line maintained in monolayer culture. Further, there was no significant difference between the oxygen consumption rates of exponential and plateau-phase monolayer cultures. The data indicate that M006
and MOlOb cells use oxygen at a rate four to fivefold less than that of M059K cells. The cell lines derived from xenografts and maintained by serial passage in vitro also differ among the three glioma sources tested. However, within each glioma series (e.g. the M006 lines), the oxygen utilization of the xenograft-derived lines maintained in vitro is similar to that of the parent cell line. When grown as subcutaneous xenografts (Table 2) , M006 xenografts consumed oxygen at a rate approximately 2.7 times lower than that of the M006 line. M059K xenografts consumed oxygen at a rate almost sevenfold lower than exponential M059K monolayers. The xenograft oxygen consumption was significantly lower in the M0106. In order to exclude the possibility that enzymatic disaggregation caused an artifactual lowering of oxygen consumption, M006 monolayers were either trypsinized as usual before measurement of oxygen concentration or treated for 1 h with the disaggregating enzyme 'cocktail' (0.025% collagenase, 0.05% pronase and 0.04% DNAase) (Allalunis-Turmer and Sieman, 1986) . No significant difference in oxygen consumption was observed.
DISCUSSION
It has been reported that human gliomas contain bioreductive enzymes [NAD(P)H-cytochrome P450 oxidoreductase, NAD(P)H -quinone oxidoreductase] (Rampling et al, 1994) , which might be involved in the reductive activation of nitroimidazoles (Cobb et al, 1990; Parliament et al, 1992; Joseph et al, 1994) . Thus, the finding that unresected, untreated human malignant gliomas failed to show avidity for the hypoxia marker ['231 ]IAZA in situ was unexpected. Because LAZA is a lipophilic agent [log P (octanol-water) = 4], it can theoretically be expected to cross the intact blood-brain barrier. Further, disruption of the blood-brain barrier in deeper regions of primary brain tumours has long been recognized, suggesting that inadequate exposure of putative hypoxic cells in deeper regions to nitroimidazoles is extremely unlikely. Measurements of IAZA tumour tissue concentration would clarify this point but would be logistically and ethically difficult to perform.
Model systems were developed to test several hypotheses for the failure of ['231] IAZA to detect hypoxic regions in gliomas: (1) inadequate drug delivery or intracellular uptake, (2) altered kinetics of nitroimidazole activation by glioma nitroreductases and (3) development of necrosis due to depletion of substrates other than oxygen. Previous work has established the feasibility of both subcutaneous and intracranial sites of tumour transplantation in immune-deficient rodents (Rana et al, 1977; Bradley et al, 1978; Shapiro et al, 1979) . The reason for using two different implantation sites was to evaluate the possibility that the intracranial microenvironment was unique with respect to oxygenation owing to differences in tumour interstitial pressure, tumour blood flow and/or vascular architecture. The adequacy of xenografted tumours as models for human gliomas in situ deserves comment. Previous studies predicted the development of an altered phenotype with repeated serial passages in mice, presumably because of genetic instability and/or selection (Shapiro and Basler, 1979) .
With serial passages, tumours may manifest altered antigenicity, cellularity, percentage tumour take and median latent period before palpable growth (Bullard et al, 1981; Horten et al, 1981; Jones et al, 1981 (Figure 1) , in a manner which is consistent with hypoxia at the edge of necrosis (Chapman et al, 1981; Urtasun et al, 1986) . This supports the notion that these drugs encounter no problem with diffusion through tumour tissue or with intracellular transport and binding. Despite the obvious differences in host species and implantation site, it is remarkable that the variable association between elevated hypoxia-marker binding and necrosis was seen both in the SCID mouse and nude rat models. (Chapman et al., 1982) .
In vitro, when [3H]misonidazole was incubated with glioma tumour fragments, there was a rise in grain density with radial distance from the surface of the fragment in a manner consistent with the presumed oxygen gradient (Franko et al, 1987) . In principle, the steeply rising portion of the curve, which begins at the surface at the lowest concentrations of oxygen, should be reproduced at progressively greater depths for incubation in greater oxygen concentrations. This was the case for the MO1Ob tumour ( Figure 2A ) and for the M006X tumour at all but the highest oxygen concentration ( Figure 2B ). The gradual rise in the latter curve could have arisen as an artifact of the shape of the tumour fragments used, which might have allowed diffusion of oxygen in the direction perpendicular to the plane of the histological section. Alternatively, considering the size of the 95% confidence limits, the shape of the curve might not be significantly different from the theoretical expectation. It is clear from the data that, given sufficient distance, both tumours were capable of metabolizing oxygen to sufficiently low levels as to yield the maximal rate of binding of misonidazole. The distance from the surface at which maximal binding of nitroimidazoles occurred is within the range of distances observed for human colon carcinomas and a melanoma and breast carcinoma and for the oxygen diffusion distance calculated for the hypoxia probe AF-2 in the IF.1 and ICC VII tumours Lewis lung carcinoma and WiDr human colon carcinoma (Olive et al, 1992) . In Table 1 , the adjusted grain density in glioma tumour fragments incubated under severe hypoxia with [3H] misonidazole is very similar to that of murine tumours for which the binding characteristics have been extensively studied (Franko et al, 1987 . On the basis of these data, it would appear that intracellular uptake, the kinetics of hypoxic activation and the binding of nitroimidazoles in human gliomas are qualitatively similar to those observed in many animal and human tumours.
Mammalian cells or tissues whose rate of oxygen consumption varies with the availability of oxygen are termed 'oxygen conformers' (Hochachka and Guppy, 1987 p. 11) . In contrast, cells or tissues whose rate of oxygen consumption is independent of oxygen availability down to very low values are classed as 'oxygen regulators'. Normal mammalian brain functions as an oxygen regulator (Kinter et al, 1984) , whereas skeletal muscle is classed as 'the most 02 conforming of all tissues' (Hochachka and Guppy, 1987, p. 11) . The extent to which malignantly transformed cells retain the respiratory characteristics of the normal tissue of origin has not been extensively investigated. We are currently examining the possibility that glioma cells exhibit an oxygenconforming phenotype. Our preliminary studies with human malignant glioma cells would suggest that the patterns of oxygen consumption observed in tumour cells are significantly different from that which would have been predicted based on the oxygen consumption behaviour of normal brain. For example, the oxygen consumption rate of M006, M059K and MO1ObX cells grown in vivo, in which pO2 values are unlikely to exceed 2-5%, was significantly less than the oxygen consumption rate of tumour cells grown in vitro in which the concentration of oxygen in the medium is near equilibrium with that of the atmosphere (18% oxygen). As other microenvironmental factors in vivo may potentially alter metabolism, it will be important to assess the extent to which oxygen concentration per se modulates respiration. In vitro studies measuring oxygen consumption rates of monolayer glioma cultures equilibrated under different oyxgen concentrations are currently in progress. Our preliminary results suggest that oxygen consumption rates of these cells conform to oxygen availability (J Allalunis-Turner, unpublished observation).
The difference in oxygen consumption rate observed between freshly explanted tumours and monolayer cultures cannot be attributed to a difference in the growth phase of the cells as the oxygen consumption rate of plateau-and exponential-phase monolayer cultures was not significantly different. In addition, these differences are unlikely to reflect loss of cell viability as oxygen consumption rates were calculated from the trace obtained immediately after electrode stabilization, within the first hour. The possibility of metabolic changes due to the effect of disaggregating enzymes has been raised (Olive et al, 1992 ), however we are not aware of published data to indicate that this could potentially account for the magnitude of the changes seen. Also, the presence of infiltrating host cells in the tumour preparation cannot account for the drop in oxygen utilization as histopathological examination of tumour sections confirms that the majority of the cells in the tumour were identical in morphology to human malignant glioma cells and indeed infiltrating cells, such as tumours, macrophages and neutrophils, themselves consume oxygen.
The finding of diminished oxygen consumption in freshly dissociated explants from xenografts compared with that of monolayer cultures suggests that, unlike normal mammalian brain, malignant gliomas display an oxygen-conforming phenotype. This is consistent with a coordinate inhibition or down-regulation of respiration in glioma cells in a 3-dimensional tumour system, as suggested by the '50-PET studies. Observations of such an effect were initially made decades ago (Warburg, 1956) , and experiments with V79 and EMT6 spheroids have shown such an effect (Freyer et al, 1984; Freyer and Sutherland, 1985) . Also, necrosis has been observed in human glioma spheroids at relatively high central oxygen levels as determined by microelectrodes (Carlsson et al, 1979 (Carlsson et al, , 1983 . If down-regulation of oxygen consumption was coordinated at a microregional level, it might provide an explanation for the variable presence of severe hypoxia adjacent to necrosis, as indicated by nitroimidazole binding in the xenografts. Our data raise the possibility that for some human gliomas, as well as in portions of the xenografts, necrosis may occur in many subregions as a result of depletion of glucose or other substrates, as opposed to oxygen. If hypoxic subregions were present, these could be below the limit of detection by SPECT imaging because of substantial volume averaging. However, the current animal model data would suggest that if substantial hypoxic volumes are present in gliomas compared with extracranial tumours or brain metastases, these regions would reasonably be expected to bind ['231 ]IAZA in detectable amounts. This leads us to postulate that the use and distribution of oxygen in human gliomas differs from extracranial tumours and brain metastases in ways that are significant. Studies of these potential differences may have important implications for the use of hypoxic cytotoxins in glioma therapy in the clinic.
